Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kymera Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-67.15 Mil. Kymera Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $34.37 Mil. Therefore, Kymera Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -195.41%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kymera Therapeutics EBITDA Margin % Related Terms
Kymera Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kymera Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KYMR vs PRAX, SYRE, CRNX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Kymera Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kymera Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kymera Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics (KYMR) has a EBITDA Margin % of -195.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kymera Therapeutics and its competitors. According to the industry distribution chart, Kymera Therapeutics ranks #691 out of 941 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Kymera Therapeutics' EBITDA Margin % too high?
Kymera Therapeutics' current EBITDA Margin % is -195.41%. Based on the distribution chart, Kymera Therapeutics ranks #691 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kymera Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kymera Therapeutics' EBITDA Margin % compare to PRAX and SYRE?
According to the Biotechnology industry distribution chart, Kymera Therapeutics ranks #691 out of 941 companies for EBITDA Margin %. This places Kymera Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kymera Therapeutics and its competitors. Kymera Therapeutics's current EBITDA Margin % is -195.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kymera Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Kymera Therapeutics (KYMR) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.30, compared to a current price of $103.26 — trading 324.9% above its estimated fair value. The current EBITDA Margin % is -195.41%. Kymera Therapeutics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kymera Therapeutics (KYMR), the current EBITDA Margin % is -195.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kymera Therapeutics (KYMR) Overvalued in 2026?
Based on GuruFocus' analysis, Kymera Therapeutics stock appears to be overvalued.
The current stock price of $103.26 is trading 324.9% above its estimated GF Value™ of $24.30.
GuruFocus considers Kymera Therapeutics to be Significantly Overvalued.
Key valuation signals for KYMR:
EBITDA Margin %: -195.41%
GF Value™: $24.30 vs. price of $103.26 (324.9% above fair value)
No single metric tells the full story. See the KYMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
46GF Score
Get the complete analysis for KYMR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYMR has been successfully added to your 
